Outgoing CombiMatrix CEO Calls Firm 'Attractive Acquisition Prospect' | GenomeWeb

This story was first published May 7.

By Justin Petrone

CombiMatrix's recent restructuring activities and "strong" balance sheet have made the firm a potential buy for companies looking to enter the molecular diagnostics market, according to the firm's top official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.